Page last updated: 2024-12-07

substance p (6-11), arg(6)-trp(7,9)-me-phe(8)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

substance P (6-11), Arg(6)-Trp(7,9)-Me-Phe(8)-: substance P antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131091
MeSH IDM0135821

Synonyms (12)

Synonym
antg
(2s)-n-[(2s)-1-[[(2r)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]-2-[[(2r)-2-[[(2s)-2-amino-3-(4-methylphenyl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-4-methylp
6-arginyl-7,9-tryptophyl-8-methylphenylalanine-substance p (6-11)
substance p (6-11), arginyl(6)-tryptophyl(7,9)-methylphenylalanine(8)-
arg(6)-d-trp(7,9)-mephe(8)-sp(6-11)
sp-ant
6-arg-7,9-trp-8-me-phe-substance p (6-11)
substance p (6-11), arg(6)-trp(7,9)-me-phe(8)-
129244-81-1
l-methioninamide, l-arginyl-d-tryptophyl-4-methyl-l-phenylalanyl-d-tryptophyl-l-leucyl-
(arg(6),trp(7,9),n-mephe(8))-substance p(6-11)
DTXSID90156126

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" When combined with a substance P (SP) analogue, which inhibits the action of multiple neuropeptides and SCLC cell growth, both in semisolid media and liquid culture, tyrphostin additively inhibited the growth of the H-345 and H-69 SCLC cell lines in liquid culture."( Effect of tyrphostin combined with a substance P related antagonist on small cell lung cancer cell growth in vitro.
Rozengurt, E; Seckl, MJ, 1996
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves of neuropeptide-induced inositol phosphate generation were dramatically displaced to the right by either 10 microM AntD or 20 microM AntG."( Substance P-related antagonists inhibit vasopressin and bombesin but not 5'-3-O-(thio)triphosphate-stimulated inositol phosphate production in Swiss 3T3 cells.
Freemont, PS; Newman, RH; Rozengurt, E; Seckl, MJ, 1995
)
0.29
"The aim of this study was to develop a stable parenteral dosage form for the investigational cytotoxic drug [Arg6, D-Trp79,MePhe8]-Substance P [6-11] (Substance P Antagonist G; Antagonist G)."( Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P [6-11].
Beijnen, JH; Bult, A; Henrar, RE; Jonkman-de Vries, JD; Kettenes-van den Bosch, JJ; Rosing, H; Talsma, H, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.00)18.7374
1990's14 (70.00)18.2507
2000's4 (20.00)29.6817
2010's1 (5.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index5.57 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]